collected into tubes containing 0.5 ml of 0.01 M citric acid and analysed for the presence of pepsin using a lateral flow test comprising two unique human monoclonal antibodies to pepsin (Reptest™, RDBiomed Ltd). The cut off value to determine pepsin positivity was 25 ng/ml.

**Results** Of 300 saliva samples tested, 19% were +ve for pepsin. 64% of subjects had all three saliva samples negative; 20% had 1 sample positive, 12% had 2 samples positive and 4% had 3 samples positive. A similar percentage of samples were positive after lunch (24%) and dinner (22%), but lower on waking (10%). Median acid exposure time was 0.3% (IQR = 0.1–0.8%, 95°-centile 3.5%). Median no. of reflux events was 52 (15–42, 77) being acid 11 (5–22.47) and non-acid 15 (3–25, 46).

Saliva samples positive for pepsin were preceded by significantly more reflux events during the 60 min interval before sampling compared to negative samples both after lunch and dinner (+ve pepsin 6 reflux (4–9) vs. -ve pepsin 3 reflux (1–5) p < 0.0001). Supine acid exposure and no. of reflux episodes was not significantly different with +ve or -ve morning samples. Subjects with 5 saliva samples +ve for pepsin had a higher ratio of proximal reflux episodes than subjects with no +ve samples (57%/range 29–40%) vs. 19%/12–33%, p < 0.02). Only 6/300 samples contained more than 250 ng/ml pepsin.

**Conclusion** Pepsin was found in the expectorated saliva of a proportion of healthy individuals who did not experience reflux symptoms, particularly post-prandially. However, only 4% of healthy subjects had 3 positive samples. An increased number of reflux episodes were found prior to giving saliva samples with detectable levels of pepsin. Our results suggest that the presence of pepsin in saliva can be a potential screening tool for GERD when at least 3 samples throughout a day are positive or samples contain more than 250 ng/ml pepsin.

**Disclosure of Interest** None Declared.

---

**PTU-150**

**CONCORDANCE BETWEEN ENDOSCOPIC ULTRASOUND (EUS) AND POSITRON EMISION TOMOGRAPHY (PET) IN THE STAGING OF UPPER GASTROINTESTINAL CANCER – A DISTRICT GENERAL EXPERIENCE**

**Introduction** Approximately 1700 patients/year are diagnosed with oesophageal or gastric cancer in Scotland. The Scottish Audit of Gastric and Oesophageal Cancer (SAGOC) previously reported under-staging of these cancers pre-operatively with curative surgery attempted too often. This resulted in incomplete resection and recurrence with a one year postoperative survival of only 53%. Increasing emphasis has therefore been placed on accurate pre-operative staging. Current guidelines advise multimodal staging with CT, EUS +/- laparoscopy if gastric involvement. Recently the use of PET staging has increased. We sought to establish the concordance between EUS and PET in the staging of upper GI cancer within a large district general hospital.

**Methods** A retrospective study was performed in patients with oesophageal or gastric cancer referred for multimodal staging with CT, EUS and PET between October 2008 and November 2011. Each case was reviewed at the local multi-disciplinary team (MDT) meeting. MDT outcome forms were collated and a casenote review performed. Baseline demographics, tumour characteristics and TNM staging were recorded.

**Results** 89 patients (45 male) were referred for both EUS and PET. The majority had adenocarcinoma (49/59, 83.1%) with 9 squamous carcinomas (15.3%) and 1 carcinoïd (1.7%). A malignant stricture prevented EUS in 3 patients while in 3 patients CT-PET revealed metastatic disease and EUS was cancelled. 55 patients (40 male) underwent staging with both modalities. Concordance of N staging between EUS and PET was 75.9%. In 13/53 patients EUS altered prior PET staging, upstaging from N0 to N1 in 12/13 (91.4%). In patients undergoing EUS-FNA (10 mediastinal, 1 sub-diaphragmatic), 2/11 (18.2%) patients were found to have malignant lymphadenopathy affecting PET negative nodes while in 1 patients a PET positive node was found to be benign. EUS was more accurate in predicting resection N stage (65%) than PET (38.9%) with both tending to underestimate. In patients with T3 disease there was a significant difference in N staging between patients undergoing resection and those treated palliatively (p < 0.05).

**Conclusion** Nodal staging by EUS and PET differs in a significant proportion of patients undergoing pre-operative work-up for upper GI cancer. In the majority of cases PET underestimates nodal staging. However, technical difficulties may preclude EUS while the finding of distant metastases at PET prior to EUS may prevent unnecessary investigations. CT and EUS remain the mainstay of pre-operative staging in oesophageal and gastric cancers but PET is a useful adjunct.

**Disclosure of Interest** None Declared.

---

**PTU-151**

**HIGH RESOLUTION MANOMETRY PROFILE OF HIATAL HERNIA IN PATIENTS BEFORE AND AFTER FUNDOPICATION**

**Introduction** Current data relating to esophageal motility evaluated by high resolution manometry(HRM) in presence of hiatal hernia(HH) is equivocal. This study was aimed to compare HRM variables in patients with HH before and after fundoplication and to evaluate diagnostic performance of HRM in detecting sliding HH.

**Methods** Sensitivity and specificity of HRM were assessed in 31 patients(20 females; mean age 48.2) with gastroesophageal reflux disease who were qualified for Nissen fundoplication and underwent preoperative HRM. Intraoperative diagnosis of HH was the gold standard. Area under curve(AUC) of receiver operating characteristic(ROC) reflecting diagnostic accuracy of HRM was also computed. Eleven patients(5 females; mean age 52.1) out of 31 were selected who underwent both: HRM before fundoplication(preoperative group) and at least 3 months after surgery(postoperative group). Manometric protocol included 10 consecutive swallows of 10 ml of water. Variables from pre and postoperative group were compared using paired Wilcoxon test.

**Results** 29 patients out of 31 were found to have HH during surgery while 14 patients had manometric criteria for HH(mean HH size was 2.44 cm). Sensitivity and specificity of HRM in detecting HH were 48% and 100% respectively. AUC under ROC curve for HRM was 0.74 indicating limited usefulness of this method; regarding threshold value of 0.8 for clinical practise. HRM profile of HH in preoperative group is characterised by significantly lower minimal basal esophagogastric junction(EGJ) pressure as well as integrated relaxation pressure(IRP) compared to postoperative group without HH. IRP values were within normal range in both examined groups(< 15 mmHg). Although mean basal EGJ pressure was lower in preoperative than in postoperative group, the difference between groups didn’t reach statistical significance. Neither DCI nor IBP was affected by fundoplication. Data is shown in table.